Do analysts recommend ALVO or NLTX?

Alvotech currently has a consensus target price of $7.60, indicating a potential upside of 110.53%. Given Alvotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Alvotech is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alvotech 2 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer SDGR or NLTX?

Schrodinger currently has a consensus price target of $20.25, indicating a potential upside of 19.96%. Given Schrodinger's stronger consensus rating and higher possible upside, equities research analysts plainly believe Schrodinger is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Schrodinger 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate MGTX or NLTX?

MeiraGTx currently has a consensus target price of $25.83, suggesting a potential upside of 85.58%. Given MeiraGTx's stronger consensus rating and higher possible upside, equities analysts plainly believe MeiraGTx is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MeiraGTx 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend NLTX or CGEM?

Cullinan Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 81.51%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cullinan Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Which has higher earnings & valuation, NLTX or CGEM?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A

Is NLTX or CGEM more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Cullinan Therapeutics N/A -51.45% -47.64%

Neoleukin Therapeutics (NLTX) Competitors

$35.34 +1.46 (+4.31%)

As of 07/2/2026

Compare

NLTX vs. COLL, ALVO, SDGR, MGTX, and CGEM

Should you buy Neoleukin Therapeutics stock or one of its competitors? MarketBeat compares Neoleukin Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neoleukin Therapeutics include Collegium Pharmaceutical (COLL), Alvotech (ALVO), Schrodinger (SDGR), MeiraGTx (MGTX), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry.

How does Neoleukin Therapeutics compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for Collegium Pharmaceutical and 0 mentions for Neoleukin Therapeutics. Collegium Pharmaceutical's average media sentiment score of 1.50 beat Neoleukin Therapeutics' score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Overall Sentiment
Collegium Pharmaceutical	Very Positive
Neoleukin Therapeutics	Neutral

Collegium Pharmaceutical has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Collegium Pharmaceutical has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$796.33M	1.51	$62.87M	$2.04	18.15
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Collegium Pharmaceutical currently has a consensus target price of $57.50, suggesting a potential upside of 55.28%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, equities analysts clearly believe Collegium Pharmaceutical is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Collegium Pharmaceutical has a net margin of 9.41% compared to Neoleukin Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Summary

Collegium Pharmaceutical beats Neoleukin Therapeutics on 14 of the 16 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVO) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Alvotech currently has a consensus target price of $7.60, indicating a potential upside of 110.53%. Given Alvotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Alvotech is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Neoleukin Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.59%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

In the previous week, Alvotech had 7 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 7 mentions for Alvotech and 0 mentions for Neoleukin Therapeutics. Alvotech's average media sentiment score of 0.79 beat Neoleukin Therapeutics' score of 0.00 indicating that Alvotech is being referred to more favorably in the media.

Company	Overall Sentiment
Alvotech	Positive
Neoleukin Therapeutics	Neutral

Alvotech has higher revenue and earnings than Neoleukin Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	1.85	$27.92M	-$0.25	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 0.5% of Alvotech shares are owned by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alvotech has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Summary

Alvotech beats Neoleukin Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Schrodinger?

Schrodinger (NASDAQ:SDGR) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Neoleukin Therapeutics has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	4.87	-$103.26M	-$1.41	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Schrodinger has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

In the previous week, Schrodinger had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for Schrodinger and 0 mentions for Neoleukin Therapeutics. Schrodinger's average media sentiment score of 1.40 beat Neoleukin Therapeutics' score of 0.00 indicating that Schrodinger is being referred to more favorably in the media.

Company	Overall Sentiment
Schrodinger	Positive
Neoleukin Therapeutics	Neutral

Neoleukin Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Schrodinger's return on equity of -30.85% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Schrodinger currently has a consensus price target of $20.25, indicating a potential upside of 19.96%. Given Schrodinger's stronger consensus rating and higher possible upside, equities research analysts plainly believe Schrodinger is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 10.1% of Schrodinger shares are held by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Schrodinger beats Neoleukin Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, MeiraGTx had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for MeiraGTx and 0 mentions for Neoleukin Therapeutics. MeiraGTx's average media sentiment score of 1.42 beat Neoleukin Therapeutics' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Overall Sentiment
MeiraGTx	Positive
Neoleukin Therapeutics	Neutral

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 7.4% of MeiraGTx shares are held by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MeiraGTx currently has a consensus target price of $25.83, suggesting a potential upside of 85.58%. Given MeiraGTx's stronger consensus rating and higher possible upside, equities analysts plainly believe MeiraGTx is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

MeiraGTx has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Neoleukin Therapeutics has lower revenue, but higher earnings than MeiraGTx. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$79.76M	16.16	-$114.20M	-$1.48	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Neoleukin Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	N/A	-54.96%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Summary

MeiraGTx beats Neoleukin Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Cullinan Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Neoleukin Therapeutics' return on equity of -37.22% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cullinan Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 81.51%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market.

In the previous week, Neoleukin Therapeutics' average media sentiment score of 0.00 equaled Cullinan Therapeutics'average media sentiment score.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Cullinan Therapeutics	Neutral

Summary

Cullinan Therapeutics beats Neoleukin Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Neoleukin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NLTX vs. The Competition

Export

Metric	Neoleukin Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$332.13M	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	-11.36	1.66	28.02	24.70
Price / Sales	N/A	127.53	540.37	99.46
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	3.19	8.17	10.96	6.46
Net Income	-$57.56M	-$3.71M	$3.57B	$337.01M
7 Day Performance	10.33%	2.59%	2.12%	1.69%
1 Month Performance	28.60%	4.41%	5.25%	3.81%
1 Year Performance	75.91%	49.43%	33.29%	23.90%

Neoleukin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NLTX Neoleukin Therapeutics	N/A	$35.34 +4.3%	N/A	+75.9%	$332.13M	N/A	N/A	90	High Trading Volume
COLL Collegium Pharmaceutical	3.4356 of 5 stars	$35.58 +2.8%	$57.50 +61.6%	+21.9%	$1.12B	$780.57M	17.44	210	Positive News
ALVO Alvotech	3.2557 of 5 stars	$3.71 +0.1%	$7.60 +105.1%	-60.7%	$1.12B	$588.90M	N/A	1,460
SDGR Schrodinger	2.7714 of 5 stars	$15.33 +1.9%	$20.25 +32.1%	-19.5%	$1.11B	$255.87M	N/A	790	Positive News
MGTX MeiraGTx	2.7995 of 5 stars	$11.60 -1.8%	$25.83 +122.7%	+85.5%	$1.09B	$81.39M	N/A	300	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NLTX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. COLL, ALVO, SDGR, MGTX, and CGEM

How does Neoleukin Therapeutics compare to Collegium Pharmaceutical?

Summary

How does Neoleukin Therapeutics compare to Alvotech?

Summary

How does Neoleukin Therapeutics compare to Schrodinger?

Summary

How does Neoleukin Therapeutics compare to MeiraGTx?

Summary

How does Neoleukin Therapeutics compare to Cullinan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. COLL, ALVO, SDGR, MGTX, and CGEM

How does Neoleukin Therapeutics compare to Collegium Pharmaceutical?

Does the media prefer COLL or NLTX?

Which has more risk and volatility, COLL or NLTX?

Which has stronger valuation and earnings, COLL or NLTX?

Do insiders & institutionals hold more shares of COLL or NLTX?

Do analysts recommend COLL or NLTX?

Is COLL or NLTX more profitable?

Summary

How does Neoleukin Therapeutics compare to Alvotech?

Do analysts recommend ALVO or NLTX?

Is ALVO or NLTX more profitable?

Does the media refer more to ALVO or NLTX?

Which has preferable valuation & earnings, ALVO or NLTX?

Do insiders & institutionals have more ownership in ALVO or NLTX?

Which has more risk & volatility, ALVO or NLTX?

Summary

How does Neoleukin Therapeutics compare to Schrodinger?

Which has preferable earnings & valuation, SDGR or NLTX?

Which has more volatility and risk, SDGR or NLTX?

Does the media refer more to SDGR or NLTX?

Is SDGR or NLTX more profitable?

Do analysts prefer SDGR or NLTX?

Do insiders and institutionals have more ownership in SDGR or NLTX?

Summary

How does Neoleukin Therapeutics compare to MeiraGTx?

Does the media prefer MGTX or NLTX?

Do institutionals and insiders hold more shares of MGTX or NLTX?

Do analysts rate MGTX or NLTX?

Which has more volatility & risk, MGTX or NLTX?

Which has stronger valuation and earnings, MGTX or NLTX?

Is MGTX or NLTX more profitable?

Summary

How does Neoleukin Therapeutics compare to Cullinan Therapeutics?

Is NLTX or CGEM more profitable?

Which has higher earnings & valuation, NLTX or CGEM?

Do insiders and institutionals have more ownership in NLTX or CGEM?

Do analysts recommend NLTX or CGEM?

Which has more volatility & risk, NLTX or CGEM?

Does the media favor NLTX or CGEM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools